CMA Report on Agentic AI's Consumer Impact

The UK's Competition and Markets Authority (CMA) has published a report analyzing the potential impact of agentic AI on consumers. The report outlines how agentic AI is currently used, its future implications, and provides guidance for businesses on mitigating risks.

CMA Guidance on Consumer Law for AI Agents

The UK's Competition and Markets Authority (CMA) has published new guidance for businesses on complying with consumer protection law when using AI agents. The guidance clarifies that businesses remain responsible for the actions of AI agents they deploy and outlines how to train them to ensure legal compliance.

FDA Warning Letter to Ivim Services LLC for Misbranded Drugs

The FDA issued a warning letter to Ivim Services LLC for introducing misbranded compounded semaglutide and tirzepatide products into interstate commerce. The agency found that Ivim's website made false or misleading claims, suggesting Ivim was the compounder when it was not, violating the Federal Food, Drug, and Cosmetic Act.

FDA Warning Letter to Good Girl LLC for False Claims

The FDA issued a warning letter to Good Girl LLC (dba GoodGirlRX) for making false and misleading claims on its website regarding compounded semaglutide and tirzepatide products. The company claimed the products were 'FDA-approved' and that GoodGirl RX was the compounder, which the FDA states is false and misbrands the drugs.

FDA Warning Letter to Peaks Curative for False Claims

The FDA issued a warning letter to Peaks Curative, LLC for making false and misleading claims on its website regarding compounded semaglutide products. The agency found that the company misrepresented its compounding practices and implied FDA approval for products that are not FDA-approved, leading to misbranding violations.

FDA Warning Letter to PharmaZee for False Claims

The FDA issued a warning letter to PharmaZee for making false and misleading claims on its website regarding compounded semaglutide and tirzepatide products. The agency found that PharmaZee misrepresented itself as the compounder and implied FDA approval for these unapproved drugs, violating the Federal Food, Drug, and Cosmetic Act.

FDA Warning Letter to Refills Health for False Claims

The FDA issued a warning letter to Refills Health, LLC for making false and misleading claims on its website regarding compounded semaglutide products. The agency found that the company misrepresented itself as the compounder and made unsubstantiated claims such as 'clinically proven,' leading to the products being considered misbranded under the FDCA.

FDA Warning Letter to Lean Rx Inc. dba SkinnyRx

The FDA issued a warning letter to Lean Rx Inc. dba SkinnyRx for misbranding compounded semaglutide and tirzepatide products. The agency cited false or misleading claims on the company's website regarding the compounding of these drugs and their relation to FDA-approved medications.

State AGs Announce Consequences for Child Predators

Multiple State Attorneys General, including Florida AG James Uthmeier, announced significant actions against child predators. The announcement highlights the rearrest of Devon Huart and the sentencing of Michael Ambrosio, contributing to a record 1400 child predators taken down in a year.

Cin Dale 3 v. Peoples Bank Corp - Affirmation of Dismissal

The Fourth Circuit Court of Appeals affirmed the dismissal of a suit brought by Cin Dale 3 against Peoples Bank Corp. The court held that the bank acted appropriately by complying with a court order to turn over funds from a depositor's account to satisfy a judgment. This ruling reinforces the ministerial role of banks in judgment enforcement.